# US 2006/0078599 A1 · Pharmaceutical composition applicable to body tissue

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0078599 A1
- Document ID: US20060078599A1
- Status: Published application
- Kind: A1
- Application number: 10/962,989
- Filed: 2004-10-12
- Published: 2006-04-13
- Earliest claimed: 2004-10-12
- Inventors: Mathew Ebmeier; Robert Lathrop
- Web page: https://patentgrep.com/patent/US20060078599A1

## CPC

- A61K 9/7015: {Drug-containing film-forming compositions, e.g. spray-on}
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 31/045: Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K 31/125: Camphor; Nuclear substituted derivatives thereof
- A61K 31/137: Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine {or methadone}
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/717: Celluloses
- A61K 47/08: containing oxygen, {e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides}
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/38: Cellulose; Derivatives thereof
- A61P 31/10: Antimycotics
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides a non-water soluble, film-forming composition which adheres to body tissue and forms a pharmaceutical carrier to provide localized delivery of an antifungal agent to a treatment site. The composition will typically include: (a) an alkyl cellulose; (b) a hydroxyalkyl cellulose; (c) a pharmaceutically acceptable polar protic solvent; (d) an antifungal agent selected from the group of naftifine, ciclopirox, terbinafine, pharmaceutically acceptable salts thereof, and combinations thereof; (e) an glycol ether; (f) an antipruritic agent selected from the group of camphor, menthol, butamben picrate, metacresol, benzyl alcohol, camphorated metacresol, juniper tar, phenol, phenolate sodium, resorcinol, camphorated metacresol, carbolic acid, and combinations,; and (g) a solubility enhancing agent, a surfactant, a wetting agent, or a combination thereof. The present invention also provides for the use of the composition composition of the present invention, in treating a fungal infection (e.g., nail fungus) in a mammal afflicted with such an infection.

## Claims

### Claim 1

A non-water soluble, film-forming composition which adheres to body tissue and forms a pharmaceutical carrier to provide localized delivery of an antifungal agent to a treatment site, said composition comprising:
(a) an alkyl cellulose present in about 0.5% (w/w) to about 3.0% (w/w) of the composition;
(b) a hydroxyalkyl cellulose present in about 2.0% (w/w) to about 10.0% (w/w) of the composition;
(c) a pharmaceutically acceptable polar protic solvent present in about 30.0% (w/w) to about 95.0% (w/w) of the composition;
(d) an antifungal agent selected from the group of naftifine, ciclopirox, terbinafine, pharmaceutically acceptable salts thereof, and combinations thereof, present in about 2.5% (w/w) to about 15% (w/w) of the composition;
(e) an glycol ether present in about 4.0% (w/w) to about 12.0% (w/w) of the composition;
(f) an antipruritic agent selected from the group of camphor, menthol, butamben picrate, metacresol, benzyl alcohol, camphorated metacresol, juniper tar, phenol, phenolate sodium, resorcinol, camphorated metacresol, carbolic acid, and combinations, present in about 1.0% (w/w) to about 5.0% (w/w) of the composition; and
(g) a solubility enhancing agent, a surfactant, a wetting agent, or a combination thereof, present in about 1.0% (w/w) to about 3.0% (w/w) of the composition.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the alkyl cellulose comprises ethyl cellulose, propyl cellulose, butyl cellulose, cellulose acetate, or a combination thereof.

### Claim 3 (depends on 1)

The composition of claim 1, wherein the alkyl cellulose comprises ethyl cellulose.

### Claim 4 (depends on 1)

The composition of claim 1, wherein the alkyl cellulose is present in about 0.75% (w/w) to about 1.25% (w/w) of the composition.

### Claim 5 (depends on 1)

The composition of claim 1, wherein the hydroxyalkyl cellulose comprises hydroxybutyl cellulose, ethylhydroxyethyl cellulose, hydroxypropyl cellulose, or a combination thereof.

### Claim 6 (depends on 1)

The composition of claim 1, wherein the hydroxyalkyl cellulose comprises hydroxypropyl cellulose.

### Claim 7 (depends on 1)

The composition of claim 1, wherein the hydroxyalkyl cellulose is present in about 2.5% (w/w) to about 7.5% (w/w) of the composition.

### Claim 8 (depends on 1)

The composition of claim 1, wherein the ratio of hydroxyalkyl cellulose to alkyl cellulose is about 1:1 to about 10:1.

### Claim 9 (depends on 1)

The composition of claim 1, wherein the ratio of hydroxyalkyl cellulose to alkyl cellulose is about 2.5:1 to about 7.5:1.

### Claim 10 (depends on 1)

The composition of claim 1, wherein the hydroxyalkyl cellulose and alkyl cellulose are present in about 2.5% (w/w) to about 15.0% (w/w) of the composition.

### Claim 11 (depends on 1)

The composition of claim 1, wherein the hydroxyalkyl cellulose and alkyl cellulose are present in about 2.5% (w/w) to about 10.0% (w/w) of the composition.

### Claim 12 (depends on 1)

The composition of claim 1, wherein the hydroxyalkyl cellulose and alkyl cellulose are present in about 2.5% (w/w) to about 8.0% (w/w) of the composition.

### Claim 13 (depends on 1)

The composition of claim 1, wherein the pharmaceutically acceptable polar protic solvent comprises a straight-chained or branched (C1-C30)alkyl substituted with one or more hydroxyl groups, a (C3-C10)cycloalkyl substituted with one or more hydroxyl groups, water, or a combination thereof.

### Claim 14 (depends on 13)

The composition of claim 13, wherein the straight-chained or branched (C1-C30)alkyl substituted with one or more hydroxyl groups comprises methanol, ethanol, iso-propanol, or tert-butanol.

### Claim 15 (depends on 1)

The composition of claim 1, wherein the pharmaceutically acceptable polar protic solvent comprises a combination of ethanol and water.

### Claim 16 (depends on 15)

The composition of claim 15, wherein the ethanol is present in about 30.0% (w/w) to about 90.0% (w/w) of the composition.

### Claim 17 (depends on 15)

The composition of claim 15, wherein the water is present in about 3.0% (w/w) to about 15.0% (w/w) of the composition.

### Claim 18 (depends on 1)

The composition of claim 1, wherein the antifungal agent comprises naftifine hydrochloride.

### Claim 19 (depends on 18)

The composition of claim 18, wherein the naftifine hydrochloride is present in about 2.5% (w/w) to about 7.5% (w/w) of the composition.

### Claim 20 (depends on 18)

The composition of claim 18, wherein the naftifine hydrochloride is present in about 7.5% (w/w) to about 15.0% (w/w) of the composition.

### Claim 21 (depends on 1)

The composition of claim 1, wherein the glycol ether is selected from the group of ethylene glycol monopropyl ether (propoxyethanol), ethylene glycol monobutyl ether (butoxyethanol), diethylene glycol monomethyl ether (methoxydiglycol), diethylene glycol monoethyl ether (ethoxydiglycol), diethylene glycol monobutyl ether (butoxydiglycol), diethylene glycol monoisopropyl ether (isopropyldiglycol), diethylene glycol monoisobutyl ether (isobutyl diglycol), propylene glycol monomethyl ether, dipropylene glycol monomethyl ether (PPG-2 methyl ether), tripropylene glycol monomethyl ether (PPG-3 methyl ether), propylene glycol n-propyl ether, dipropylene glycol n-propyl ether (PPG-2 propyl ether), propylene glycol monobutyl ether, dipropylene glycol monobutyl ether (PPG-2 butyl ether), propylene glycol monoisobutyl ether, dipropylene glycol dimethyl ether, and combinations thereof.

### Claim 22 (depends on 1)

The composition of claim 1, wherein the glycol ether comprises diethylene glycol monoethyl ether (DGME).

### Claim 23 (depends on 1)

The composition of claim 1, wherein the glycol ether is present in about 6.0% (w/w) to about 10.0% (w/w) of the composition.

### Claim 24 (depends on 1)

The composition of claim 1, wherein the antipruritic agent comprises benzyl alcohol.

### Claim 25 (depends on 1)

The composition of claim 1, wherein the antipruritic agent is present in about 1.5% (w/w) to about 4.5% (w/w) of the composition.

### Claim 26 (depends on 1)

The composition of claim 1, wherein the solubility enhancing agent, surfactant, wetting agent, or combination thereof, comprises sodium laureth ether sulfate (SLES).

### Claim 27 (depends on 1)

The composition of claim 1, wherein the solubility enhancing agent, surfactant, wetting agent, or combination thereof, is present in about 1.5% (w/w) to about 2.5% (w/w) of the composition.

### Claim 28 (depends on 1)

The composition of claim 1, further comprising a polymer having bioadhesive properties.

### Claim 29 (depends on 28)

The composition of claim 28, wherein said polymer having bioadhesive properties comprises polyacrylic acid, polyvinylpyrrolidone, sodium carboxymethyl cellulose, copolymers of lactic and glycolic acids, polycaprolactone, polyorthoesters, polyphosphazene, cellulose acetate, polyvinyl acetate, polyisobutylene, or a combination thereof.

### Claim 30 (depends on 1)

The composition of claim 1, further comprising a permeation enhancer.

### Claim 31 (depends on 1)

The composition of claim 1, further comprising a component which acts to adjust the kinetics or erodability of the pharmaceutical carrier.

### Claim 32 (depends on 31)

The composition of claim 31, wherein the component which acts to adjust the kinetics of erodability of the pharmaceutical carrier comprises a water soluble polymer, copolymers of lactic and glycolic acids, polycaprolactone, polyorthoesters, polyphosphazene, and mixtures thereof.

### Claim 33

A non-water soluble, film-forming composition which adheres to body tissue and forms a pharmaceutical carrier to provide localized delivery of naftifine, or a pharmaceutically acceptable salt thereof, to a treatment site, said composition comprising:
(a) ethyl cellulose;
(b) hydroxypropyl cellulose;
(c) purified water;
(d) ethanol;
(e) naftifine, or a pharmaceutically acceptable salt thereof;
(f) diethylene glycol monoethyl ether (DGME);
(g) benzyl alcohol; and
(h) sodium laureth ether sulfate (SLES).

### Claim 34

A non-water soluble, film-forming composition which adheres to body tissue and forms a pharmaceutical carrier to provide localized delivery of naftifine, or a pharmaceutically acceptable salt thereof, to a treatment site, said composition comprising:
(a) ethyl cellulose present in about 1.0% (w/w) of the composition;
(b) hydroxypropyl cellulose present in about 5.0% (w/w) of the composition;
(c) purified water present in about 6.0% (w/w) of the composition;
(d) ethanol 190 present in about 70.0% (w/w) of the composition;
(e) naftifine, or a pharmaceutically acceptable salt thereof, present in about 5.0% (w/w) of the composition;
(f) diethylene glycol monoethyl ether (DGME) present in about 8.0% (w/w) of the composition;
(g) benzyl alcohol present in about 3.0% (w/w) of the composition; and
(h) sodium laureth ether sulfate (SLES) present in about 2.0% (w/w) of the composition.

### Claim 35

A non-water soluble, film-forming composition which adheres to body tissue and forms a pharmaceutical carrier to provide localized delivery of naftifine, or a pharmaceutically acceptable salt thereof, to a treatment site, said composition comprising:
(a) ethyl cellulose present in about 1.0% (w/w) of the composition;
(b) hydroxypropyl cellulose present in about 5.0% (w/w) of the composition;
(c) purified water present in about 6.0% (w/w) of the composition;
(d) ethanol 190 present in about 65.0% (w/w) of the composition;
(e) naftifine, or a pharmaceutically acceptable salt thereof, present in about 10.0% (w/w) of the composition;
(f) diethylene glycol monoethyl ether (DGME) present in about 8.0% (w/w) of the composition;
(g) benzyl alcohol present in about 3.0% (w/w) of the composition; and
(h) sodium laureth ether sulfate (SLES) present in about 2.0% (w/w) of the composition.

### Claim 36

A non-water soluble, film-forming composition which adheres to body tissue and forms a pharmaceutical carrier to provide localized delivery of naftifine, or a pharmaceutically acceptable salt thereof, to a treatment site, said composition consisting essentially of:
(a) ethyl cellulose;
(b) hydroxypropyl cellulose;
(c) purified water;
(d) ethanol;
(e) naftifine, or a pharmaceutically acceptable salt thereof;
(f) diethylene glycol monoethyl ether (DGME);
(g) benzyl alcohol; and
(h) sodium laureth ether sulfate (SLES).

### Claim 37

A non-water soluble, film-forming composition which adheres to body tissue and forms a pharmaceutical carrier to provide localized delivery of naftifine, or a pharmaceutically acceptable salt thereof, to a treatment site, said composition consisting essentially of:
(a) ethyl cellulose present in about 1.0% (w/w) of the composition;
(b) hydroxypropyl cellulose present in about 5.0% (w/w) of the composition;
(c) purified water present in about 6.0% (w/w) of the composition;
(d) ethanol 190 present in about 70.0% (w/w) of the composition;
(e) naftifine, or a pharmaceutically acceptable salt thereof, present in about 5.0% (w/w) of the composition;
(f) diethylene glycol monoethyl ether (DGME) present in about 8.0% (w/w) of the composition;
(g) benzyl alcohol present in about 3.0% (w/w) of the composition; and
(h) sodium laureth ether sulfate (SLES) present in about 2.0% (w/w) of the composition.

### Claim 38

A non-water soluble, film-forming composition which adheres to body tissue and forms a pharmaceutical carrier to provide localized delivery of naftifine, or a pharmaceutically acceptable salt thereof, to a treatment site, said composition consisting essentially of:
(a) ethyl cellulose present in about 1.0% (w/w) of the composition;
(b) hydroxypropyl cellulose present in about 5.0% (w/w) of the composition;
(c) purified water present in about 6.0% (w/w) of the composition;
(d) ethanol 190 present in about 65.0% (w/w) of the composition;
(e) naftifine, or a pharmaceutically acceptable salt thereof, present in about 10.0% (w/w) of the composition;
(f) diethylene glycol monoethyl ether (DGME) present in about 8.0% (w/w) of the composition;
(g) benzyl alcohol present in about 3.0% (w/w) of the composition; and
(h) sodium laureth ether sulfate (SLES) present in about 2.0% (w/w) of the composition.

### Claim 39 (depends on 1)

A method for inhibiting a fungus, the method comprising contacting the fungus with an effective amount of the composition of claim 1.

### Claim 40 (depends on 39)

The method of claim 39 wherein the contacting is in vitro.

### Claim 41 (depends on 39)

The method of claim 39 wherein the contacting is in vivo.

### Claim 42 (depends on 1)

A method for treating a fungal infection in a mammal in need of such treatment, said method comprising contacting the fungal infection with an effective amount of the composition of claim 1.

### Claim 43 (depends on 42)

The method of claim 42, wherein the fungal infection is present on a topical surface of the mammal.

### Claim 44 (depends on 42)

The method of claim 42, wherein the fungal infection is present on the nail of the mammal, under the nail of the mammal, or a combination thereof.

### Claim 45 (depends on 42)

The method of claim 42, wherein the nail is present on a toe of the mammal.

### Claim 46 (depends on 42)

The method of claim 42, wherein the nail is present on a hand of the mammal.

### Claim 47 (depends on 42)

The method of claim 42, wherein the contacting comprises spraying, dipping, or direct application by finger or swab.

### Claim 48 (depends on 42)

The method of claim 42, wherein as the composition dries, it forms a hydrated film.

### Claim 49 (depends on 42)

The method of claim 42, further comprising removing the composition from the mammal with a polar protic solvent.

### Claim 50 (depends on 49)

The method of claim 49, wherein the polar protic solvent comprises a straight-chained or branched (C1-C30)alkyl substituted with one or more hydroxyl groups, a (C3-C10)cycloalkyl substituted with one or more hydroxyl groups, water, or a combination thereof.
